---
title: "Ultragenyx Pharma | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 136 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285258429.md"
datetime: "2026-05-05T20:13:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285258429.md)
  - [en](https://longbridge.com/en/news/285258429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285258429.md)
---

# Ultragenyx Pharma | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 136 M

Revenue: As of FY2026 Q1, the actual value is USD 136 M, missing the estimate of USD 158.41 M.

EPS: As of FY2026 Q1, the actual value is USD -1.84, missing the estimate of USD -1.5156.

EBIT: As of FY2026 Q1, the actual value is USD -169 M.

### Financial Results for Q1 2026

#### Total Revenue

Total revenue for the first quarter of 2026 was $136 million, compared to $139 million for the first quarter of 2025, representing a decrease of $3 million year-over-year . Product sales were $89 million in Q1 2026, down from $91 million in Q1 2025 . Royalty revenue was $47 million in Q1 2026, compared to $48 million in Q1 2025 .

#### Segment Revenue

-   **Crysvita Revenue**: Total Crysvita revenue was $93 million in Q1 2026, down from $103 million in Q1 2025 . This includes product sales in Latin America and Türkiye of $46 million (down from $55 million in Q1 2025) and royalty revenue from the U.S. and Canada of $39 million (down from $41 million in Q1 2025) . Royalty revenue from Europe was $8 million (up from $7 million in Q1 2025) .
-   **Dojolvi Revenue**: Dojolvi revenue was $18 million in Q1 2026, an increase from $17 million in Q1 2025 .
-   **Evkeeza Revenue**: Evkeeza revenue was $18 million in Q1 2026, significantly up from $11 million in Q1 2025 .
-   **Mepsevii Revenue**: Mepsevii revenue was $7 million in Q1 2026, a decrease from $8 million in Q1 2025 .

#### Operating Expenses

Total operating expenses for the first quarter of 2026 were $305 million, an increase from $282 million in Q1 2025 . **Cost of Sales**: Cost of sales increased to $30 million in Q1 2026 from $29 million in Q1 2025 . **Research and Development (R&D)**: R&D expenses increased to $187 million in Q1 2026 from $166 million in Q1 2025 . **Selling, General and Administrative (SG&A)**: SG&A expenses were $88 million in Q1 2026, slightly up from $87 million in Q1 2025 .

#### Net Loss

Net loss for the first quarter of 2026 was - $185 million, compared to a net loss of - $151 million for the first quarter of 2025 . Loss from operations was - $169 million in Q1 2026, compared to - $143 million in Q1 2025 .

#### Cash Flow

Net cash used in operations for the three months ended March 31, 2026, was - $197 million . This includes the payment of annual bonuses and $38 million of payments related to UX143 manufacturing activities .

#### Unique Metrics

Non-cash stock-based compensation for Q1 2026 was $30 million, down from $40 million in Q1 2025 . Restructuring expense for Q1 2026 was $30 million, with no comparable expense in Q1 2025 .

#### Balance Sheet Data

As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $534 million, down from $737 million as of December 31, 2025 . Working capital was $332 million as of March 31, 2026, decreasing from $567 million as of December 31, 2025 . Total assets were $1,296 million, down from $1,532 million . Total stockholders’ equity (deficit) was - $236 million as of March 31, 2026, compared to - $80 million as of December 31, 2025 .

#### Outlook / Guidance

Ultragenyx Pharmaceutical Inc. reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, excluding potential new product launches . The company also reaffirms full year 2026 Crysvita revenue guidance of $500 million to $520 million and Dojolvi revenue guidance of $100 million to $110 million . Combined Research and Development (R&D) and Selling, General and Administrative (SG&A) expenses for 2026 are expected to be flat to slightly down versus 2025, with a projected decrease of at least 15% in 2027, as the company remains on track for profitability in 2027 .

### Related Stocks

- [RARE.US](https://longbridge.com/en/quote/RARE.US.md)

## Related News & Research

- [Ultragenyx Shareholders Approve Incentive Plan, Elect Directors](https://longbridge.com/en/news/286809118.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Royce Small-Cap Trust (NYSE: RVT) as of Apr 30, 2026 | RVT Stock News](https://longbridge.com/en/news/287103750.md)